Results 51 to 60 of about 3,351 (178)
Frontiers in Oncology, 2021 Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis.
Ting-Ting Yang +17 more
doaj +1 more source
Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
Frontiers in Immunology, 2022 IntroductionRelapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) has poor clinical outcomes when treated with conventional salvage chemotherapy.
Xianggui Yuan +9 more
doaj +1 more source
Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. [PDF]
INTRODUCTION: Blastoid variant-mantle cell lymphoma (BV-MCL) represents an aggressive subset of patients with no established standard of care treatment approach.
Brem, Elizabeth +6 more
core +1 more source
Canadian Journal of Health Technologies, 2021 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire +3 more sources
British Journal of Haematology, EarlyView.Summary BRUIN CLL‐321 is the first prospective, randomized study conducted in covalent BTK inhibitor (cBTKi) pretreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients. In this heavily pretreated population, pirtobrutinib significantly improved progression‐free survival (PFS) compared to investigator's choice (IC) of ...
Shuhua Yi +14 more
wiley +1 more source
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib. [PDF]
First-generation Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been associated with an increased risk of cardiovascular toxicities. Zanubrutinib is a more selective, next-generation BTK inhibitor.
Brown, Jennifer +10 more
core +1 more source
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations : a pooled analysis from four clinical trials [PDF]
, 2021 TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing
Ahn, Inhye E. +9 more
core +1 more source
Cancer Medicine, Volume 15, Issue 2, February 2026.ABSTRACT Background Mature B‐cell neoplasms chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and waldenström macroglobulinaemia (WM) are highly prevalent in older populations. Aims This study quantified the incidence, prevalence and relative survival/mortality rate in Australia for CLL/SS and WM and reported the past trends. Materials
Dieu Nguyen +6 more
wiley +1 more source
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
Therapeutics and Clinical Risk Management, 2022 Anagha Deshpande,1 Javier Munoz2 1Mayo Clinic Alix School of Medicine, Scottsdale, AZ, USA; 2Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USACorrespondence: Anagha Deshpande, Mayo Clinic Alix School of Medicine, 13400 E Shea Blvd ...
Deshpande A, Munoz J
doaj
Clinical and Translational Science, 2020 This thorough QT (TQT) study evaluated the effect of zanubrutinib on electrocardiogram (ECG) parameters by using concentration‐QTc (C‐QTc) analysis as the primary analysis for this study.
Song Mu +9 more
doaj +1 more source